| Literature DB >> 24899497 |
Aoshuang Chen1, Yajun Geng2, Hanzhong Ke2, Laura Constant2, Zhaoqi Yan2, Yue Pan2, Patricia Lee2, Isaiah Tan2, Kurt Williams2, Samantha George2, Gnanasekar Munirathinam2, Catherine A Reardon3, Godfrey S Getz3, Bin Wang4, Guoxing Zheng1.
Abstract
The immunosuppressant dexamethasone was shown to preferentially deplete CD4+ effector T cells while sparing regulatory T cells (Tregs) in vivo. In the current study, we show that it also preferentially depletes B-2 cells while sparing B-1 cells. In the ApoE(-/-) mouse model of atherosclerosis, in which both Tregs and B-1 cells are thought to play an atheroprotective role, we show that HSP60-targeted immunization in the presence of dexamethasone raises Ag-reactive Tregs and B-1 cells concomitantly and reduces the severity of atherosclerosis. These results indicate that dexamethasone is an adjuvant that potentiates both the Treg and B-1 responses to immunogens. This study shows that B-1 cells with a specificity for a disease-relevant Ag can be raised in vivo by immunization.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24899497 PMCID: PMC4153946 DOI: 10.4049/jimmunol.1302469
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422